Reynolds, president and chief executive of Ltd (NYSEMKTS:VNRX), discusses with Proactive Investors their Q1 2018 earnings.
The company reported a slower first quarter cash burn rate while growing cash reserves.
For the period ended March 31, it increased its cash and equivalents to US$14.3mln, compared to US$10.1mln in the previous quarter.
This week Volition entered into a sales and distribution partnership with Active Motif that will pave the way for the sale of a range of research-use-only (RUO) kits based on its proprietary Nucleosomics technology.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...
FOR OUR FULL DISCLAIMER CLICK HERE